中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (31): 5706-5710.doi: 10.3969/j.issn.2095-4344.2012.31.002

• 肝移植 liver transplantation • 上一篇    下一篇

索拉非尼治疗肝细胞性肝癌肝移植后的复发

陆 雷1，王 轩1，张 斌1，张冬华1，顾劲扬2   

  1. 1解放军第八一医院肝脏移植中心，江苏省南京市 210002；
    2南京鼓楼医院肝胆外科，江苏省南京市 210008
  • 收稿日期:2011-12-26 修回日期:2012-02-01 出版日期:2012-07-29 发布日期:2012-07-29
  • 作者简介:陆雷★，男，1978年生，江苏省射阳市人，汉族，2009年南京大学医学院毕业，硕士，主治医师，主要从事肝脏外科研究。 sheyanglei@ 163.com

Effects of sorafenib on recurrent hepatocelluar carcinoma after liver transplantation

Lu Lei1, Wang Xuan1, Zhang Bin1, Zhang Dong-hua1, Gu Jin-yang2   

  1. 1Center for Liver Transplantation, the 81 Hospital of Chinese PLA, Nanjing 210002, Jiangsu Province, China;
    2Department of Hepatobiliary Surgery, the Drum Tower Hospital of Nanjing, Nanjing 210002, Jiangsu Province, China
  • Received:2011-12-26 Revised:2012-02-01 Online:2012-07-29 Published:2012-07-29
  • About author:Lu Lei★, Master, Attending physician, Center for Liver Transplantation, the 81 Hospital of Chinese PLA, Nanjing 210002, Jiangsu Province, China sheyanglei@163.com

PDF

671

被引次数

10

摘要：

背景：肝细胞肝癌肝移植后肿瘤复发转移十分常见，肿瘤进展迅速，缺乏有效治疗方法。
目的：观察索拉非尼联合介入治疗肝细胞性肝癌肝脏移植后复发的疗效。
方法：选择24例肝细胞性肝癌肝移植后肿瘤复发患者，其中单纯接受介入治疗者16例，接受索拉非尼联合介入治疗者8例，通过Log-rank检验比较两组患者移植后6个月生存率、1年生存率、移植后无瘤生存时间。
结果与结论：介入治疗组移植后平均无瘤生存时间为95 d，联合治疗组为100 d，两组间差异无显著性意义(P=0.280 5)。移植后终生随访，介入化疗组16例全部死亡，中位生存时间为211 d，6个月生存率为69%，1年生存率为25%。联合治疗组死亡2例，6个月生存率为100%，1年生存率为100%，两组间差异有显著性意义(P < 0.000 1)。说明对于肝细胞性肝癌肝移植后肿瘤复发患者，采用索拉非尼+介入治疗联合治疗方案可显著提高患者生存期及生存率。

关键词: 索拉非尼, 肝细胞性肝癌, 肝移植, 肿瘤复发, 联合治疗

Abstract:

BACKGROUND: Recurrent hepatocelluar carcinoma is very common after liver transplantation. There are no effective therapies for recurrent hepatocelluar carcinoma due to the rapid progress of tumor.
OBJECTIVE: To observe the effects of sorafenib plus transcatheter arterial chemoembolization (TACE) and adjuvant chemotherapy in patients with recurrent hepatocelluar carcinoma after liver transplantation.
METHODS: The clinical data of 24 patients with recurrent hepatocelluar carcinoma after liver transplantation were analyzed. Sixteen patients were only treated with TACE and adjuvant chemotherapy (control group); eight patients were treated with sorafenib plus TACE and adjuvant chemotherapy (combined group). The survival rates of 6 months and 1 year as well as tumor-free survival time were compared between two groups by Log-rank test.
RESULTS AND CONCLUSION: The patients in the control group all died within 95 days of tumor-free survival time, whereas 100 days in the combined group, and there was no significant difference between two groups (P=0.280 5). During the follow-up, 16 patients in the control group were dead within 211 days of median survival time; the 6-month and 1-year overall survival rates of control group were 69% and 25%, respectively. Two patients were dead in the combined group within 1 100 days of the median survival time, the 6-month and 1-year overall survival rates were both 100%. There was significant difference in 6-month and 1-year overall survival rates between two groups (P < 0.000 1). Sorafenib plus TACE and adjuvant chemotherapy may prolong the survival of patients with recurrent hepatocelluar carcinoma after liver transplantation.

中图分类号: